Breaking News

Cambridge Major Sites Inspected, Launches API

May 12, 2011

Pre-Approval Inspection leads to commercial API launch

The Germantown, WI facility of Cambridge Major Laboratories (CML) has undergone its first FDA inspection and commercial launch of an API. The company’s manufacturing facilities were the subject of a FDA inspection, which included a pre-approval inspection (PAI) and a general quality systems inspection of both sites.

The FDA inspection represents the first for CML's newest, large-scale API manufacturing facility and the company's seventh inspection in the past nine years. CML currently manufactures more than a dozen commercial products including innovative new drugs, generic substances, and medical imaging agents.

“The inspection and subsequent commercial launch is a major milestone for CML, which is the first for our new, state-of-the-art, large-scale API facility,” said Brian Scanlan, CML's president and chief executive officer. “Our objective, as always, is to ensure that our systems are in compliance with FDA requirements. I am very pleased with the outcome of the inspection which demonstrates the full devotion of the management and employees.”

Within two months of the successful PAI, the FDA announced approval of the product, which represents the first commercial product produced in CML's new facility. “The NDA approval is a significant milestone for our newest facility and a clear sign that we are open for business at the facility,” said Mr. Scanlan.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks